Multicenter European Pilot Study of 90Yttrium-Ibritumomab Tiuxetan as First Line Therapy for Stage III - IV Follicular Lymphoma (and Selected Patients With Extended Stage II) Followed by Consolidation Rituximab for Patients in Complete Remission But With Persistent Molecular Disease.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2016
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 05 Nov 2016 This trial was completed in Austria (end date: 2013-09-10), according to European Clinical Trials Database record.
- 13 Dec 2010 Interim results presented a the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH-2010)
- 13 Dec 2010 Status changed from recruiting to active, no longer recruiting.